Boston Scientific (BSX) Financials

$106.09 +1.59 (+1.52%)

Closing price 03:59 PM Eastern

Extended Trading

$106.42 +0.33 (+0.31%)

As of 07:27 PM Eastern

Annual Income Statements for Boston Scientific

This table shows Boston Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	1,853	1,570	642	985	-115	4,700	1,671	104	347	-239
Consolidated Net Income / (Loss)	1,846	1,592	698	1,041	-82	4,700	1,671	104	347	-239
Net Income / (Loss) Continuing Operations	1,846	1,592	698	1,040	-81	4,700	1,671	105	347	-239
Total Pre-Tax Income	2,282	1,985	1,141	1,076	-79	687	1,422	933	177	-650
Total Operating Income	2,603	2,343	1,649	1,199	-80	1,518	1,506	1,285	447	-283
Total Gross Profit	11,490	9,896	8,727	8,177	6,448	7,620	7,011	6,455	5,962	5,304
Total Revenue	16,747	14,240	12,682	11,888	9,913	10,735	9,823	9,048	8,386	7,477
Operating Revenue	16,747	14,240	12,682	11,888	9,913	10,735	9,823	9,048	8,386	7,477
Total Cost of Revenue	5,257	4,345	3,956	3,711	3,465	3,116	2,813	2,593	2,424	2,173
Operating Cost of Revenue	5,257	4,345	3,956	3,711	3,465	3,116	2,813	2,593	2,424	2,173
Total Operating Expenses	8,887	7,552	7,079	6,978	6,528	6,102	5,504	5,170	5,515	5,587
Selling, General & Admin Expense	5,984	5,190	4,520	4,359	3,787	3,941	3,569	3,294	3,099	2,873
Research & Development Expense	1,615	1,414	1,323	1,204	1,143	1,174	1,113	997	920	876
Amortization Expense	856	828	803	741	789	699	599	565	545	495
Other Operating Expenses / (Income)	33	46	69	-29	45	65	70	68	79	70
Impairment Charge	386	58	132	370	533	105	35	4.00	11	19
Restructuring Charge	16	69	24	40	52	38	36	37	28	26
Other Special Charges / (Income)	-5.00	-53	208	294	178	80	82	205	833	1,228
Total Other Income / (Expense), net	-305	-358	-508	-123	1.00	-831	-85	-353	-270	-367
Interest Expense	305	265	470	341	361	473	241	229	233	284
Income Tax Expense	436	393	443	36	2.00	-4,013	-249	828	-170	-411
Preferred Stock Dividends Declared	0.00	23	55	55	33	0.00	0.00	-	-	-
Net Income / (Loss) Attributable to Noncontrolling Interest	-8.00	-1.00	0.00	0.00	-	-	-	-	-	-
Basic Earnings per Share	$1.26	$1.08	$0.45	$0.69	($0.08)	$3.38	$1.21	$0.08	$0.26	($0.18)
Weighted Average Basic Shares Outstanding	1.47B	1.45B	1.43B	1.42B	1.42B	1.39B	1.38B	1.37B	1.36B	1.34B
Diluted Earnings per Share	$1.25	$1.07	$0.45	$0.69	($0.08)	$3.33	$1.19	$0.08	$0.25	($0.18)
Weighted Average Diluted Shares Outstanding	1.49B	1.46B	1.44B	1.43B	1.42B	1.41B	1.40B	1.39B	1.38B	1.34B
Weighted Average Basic & Diluted Shares Outstanding	1.48B	1.47B	1.43B	1.43B	1.42B	1.40B	1.38B	1.37B	1.33B	1.33B

This table shows Boston Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	674	565	469	324	495	504	505	261	300	126	174
Consolidated Net Income / (Loss)	672	563	468	322	493	504	504	270	314	140	188
Net Income / (Loss) Continuing Operations	672	562	469	322	493	504	505	270	313	139	188
Total Pre-Tax Income	805	585	669	420	608	505	610	426	444	395	245
Total Operating Income	921	675	733	520	675	584	693	514	552	402	358
Total Gross Profit	3,210	3,095	2,897	2,850	2,648	2,579	2,426	2,542	2,349	2,232	2,191
Total Revenue	4,663	4,562	4,209	4,120	3,856	3,725	3,527	3,599	3,389	3,242	3,170
Operating Revenue	4,663	4,562	4,209	4,120	3,856	3,725	3,527	3,599	3,389	3,242	3,170
Total Cost of Revenue	1,453	1,466	1,312	1,270	1,209	1,146	1,101	1,058	1,040	1,011	979
Operating Cost of Revenue	1,453	1,466	1,312	1,270	1,209	1,146	1,101	1,058	1,040	1,011	979
Total Operating Expenses	2,288	2,420	2,164	2,330	1,973	1,994	1,733	2,028	1,797	1,831	1,833
Selling, General & Admin Expense	1,597	1,612	1,562	1,446	1,364	1,379	1,242	1,354	1,215	1,163	1,132
Research & Development Expense	443	459	407	383	366	362	356	359	337	330	339
Amortization Expense	219	224	205	213	214	207	208	210	203	199	202
Other Operating Expenses / (Income)	14	9.00	5.00	9.00	10	12	11	12	11	35	11
Restructuring Charge	10	4.00	8.00	1.00	3.00	18	15	16	20	5.00	4.00
Other Special Charges / (Income)	5.00	-1.00	-23	2.00	17	15	-99	19	12	98	20
Total Other Income / (Expense), net	-116	-73	-65	-100	-67	-78	-84	-88	-108	-6.00	-114
Interest Expense	82	80	79	77	69	64	66	70	65	64	63
Other Income / (Expense), net	-34	-	14	-23	2.00	-14	-18	-18	-43	58	-51
Income Tax Expense	133	23	200	98	115	1.00	105	156	131	256	57
Net Income / (Loss) Attributable to Noncontrolling Interest	-2.00	-7.00	0.00	-2.00	1.00	-1.00	0.00	0.00	0.00	-	0.00
Basic Earnings per Share	$0.46	$0.38	$0.32	$0.22	$0.34	$0.35	$0.34	$0.18	$0.21	$0.09	$0.12
Weighted Average Basic Shares Outstanding	1.48B	1.47B	1.47B	1.47B	1.47B	1.45B	1.46B	1.45B	1.44B	1.43B	1.43B
Diluted Earnings per Share	$0.45	$0.38	$0.32	$0.22	$0.33	$0.34	$0.34	$0.18	$0.21	$0.09	$0.12
Weighted Average Diluted Shares Outstanding	1.49B	1.49B	1.49B	1.48B	1.48B	1.46B	1.48B	1.46B	1.45B	1.44B	1.44B
Weighted Average Basic & Diluted Shares Outstanding	1.48B	1.48B	1.47B	1.47B	1.47B	1.47B	1.46B	1.46B	1.44B	1.43B	1.43B

This table details how cash moves in and out of Boston Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-450	-70	-1,042	173	1,388	-232	-187	530	87	-223
Net Cash From Operating Activities	3,435	2,503	1,526	1,870	1,508	1,836	310	1,426	1,182	691
Net Cash From Continuing Operating Activities	3,434	2,504	1,527	1,871	1,508	1,838	311	1,426	1,182	691
Net Income / (Loss) Continuing Operations	1,846	1,592	698	1,041	-82	4,700	1,671	104	347	-239
Consolidated Net Income / (Loss)	1,846	1,592	698	1,041	-82	4,700	1,671	104	347	-239
Depreciation Expense	1,269	1,196	1,136	1,093	1,123	1,011	894	844	815	769
Amortization Expense	51	6.00	32	34	58	46	6.00	10	22	36
Non-Cash Adjustments To Reconcile Net Income	656	407	541	-24	432	713	-91	237	68	331
Changes in Operating Assets and Liabilities, net	-388	-697	-880	-273	-23	-4,632	-2,169	231	-70	-206
Net Cash From Investing Activities	-5,687	-2,574	-2,011	-1,596	-411	-5,041	-1,921	-1,010	-887	-2,186
Net Cash From Continuing Investing Activities	-5,687	-2,575	-2,011	-1,596	-411	-5,042	-1,922	-1,010	-887	-2,186
Purchase of Property, Plant & Equipment	-790	-711	-588	-554	-376	-461	-316	-319	-376	-247
Acquisitions	-4,640	-1,811	-1,542	-2,258	-3.00	-4,382	-1,448	-560	-408	-1,734
Purchase of Investments	-280	-87	32	279	-146	-348	-172	-131	-132	-266
Sale of Property, Plant & Equipment	3.00	4.00	12	14	12	7.00	14	0.00	29	0.00
Divestitures	0.00	0.00	5.00	826	15	90	0.00	0.00	-	-
Other Investing Activities, net	20	30	70	82	87	52	0.00	0.00	-	-
Net Cash From Financing Activities	1,814	5.00	-548	-95	293	2,973	1,432	110	-206	1,276
Net Cash From Continuing Financing Activities	1,813	5.00	-547	-95	294	2,973	1,431	110	-206	1,277
Repayment of Debt	-317	-4.00	-3,435	0.00	-6,843	-5,135	-1,171	-3,216	-820	-1,715
Payment of Dividends	0.00	-28	-55	-55	-28	0.00	0.00	-	-	-
Issuance of Debt	2,169	0.00	3,270	0.00	5,844	7,929	2,576	3,339	630	3,100
Issuance of Common Equity	230	182	136	110	1,086	123	101	85	111	114
Other Financing Activities, net	-269	-145	-463	-150	-205	56	-75	-98	-127	-222
Effect of Exchange Rate Changes	-11	-4.00	-9.00	-6.00	-2.00	-	-8.00	4.00	-2.00	-4.00
Cash Interest Paid	250	259	450	338	359	449	262	235	233	283
Cash Income Taxes Paid	656	512	662	302	207	242	1,037	42	94	80

This table details how cash moves in and out of Boston Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	314	-2,044	-412	565	1,441	-77	512	-142	-363	628	40
Net Cash From Operating Activities	541	1,456	1,002	813	164	957	698	658	190	807	470
Net Cash From Continuing Operating Activities	541	1,454	1,004	813	163	958	697	656	193	807	472
Net Income / (Loss) Continuing Operations	672	562	469	322	493	504	504	270	314	140	188
Consolidated Net Income / (Loss)	672	562	469	322	493	504	504	270	314	140	188
Depreciation Expense	325	348	306	311	304	313	300	298	285	294	284
Amortization Expense	81	51	-	-	-	-	3.00	-	-	-	7.00
Non-Cash Adjustments To Reconcile Net Income	148	117	49	377	113	158	56	76	117	6.00	205
Changes in Operating Assets and Liabilities, net	-685	376	180	-197	-747	-17	-166	9.00	-523	367	-212
Net Cash From Investing Activities	-500	-3,704	-1,427	-271	-285	-1,053	-197	-840	-484	-183	-225
Net Cash From Continuing Investing Activities	-500	-3,705	-1,426	-272	-284	-1,053	-198	-840	-484	-182	-223
Purchase of Property, Plant & Equipment	-187	-277	-179	-155	-179	-267	-190	-143	-111	-212	-150
Acquisitions	-239	-3,418	-1,127	-48	-47	-793	-	-643	-375	-	-71
Purchase of Investments	-77	-16	-125	-73	-66	2.00	-16	-63	-10	7.00	-21
Other Investing Activities, net	3.00	4.00	5.00	4.00	7.00	7.00	7.00	7.00	9.00	16	18
Net Cash From Financing Activities	233	214	7.00	24	1,569	15	16	43	-69	1.00	-199
Net Cash From Continuing Financing Activities	234	213	7.00	24	1,569	15	16	43	-69	2.00	-200
Repayment of Debt	-1,275	187	-	-	-504	-	-41	37	0.00	-	-155
Issuance of Debt	1,558	2.00	22	-	2,145	-	-	-	0.00	-	-
Issuance of Common Equity	115	28	96	26	80	17	75	27	63	19	59
Other Financing Activities, net	-164	-4.00	-111	-2.00	-152	-2.00	-18	-7.00	-118	-4.00	-90
Effect of Exchange Rate Changes	39	-9.00	6.00	-1.00	-7.00	4.00	-5.00	-3.00	0.00	3.00	-6.00

This table presents Boston Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	39,395	35,136	32,469	32,229	30,777	30,565	20,999	19,042	18,096	18,133
Total Current Assets	6,920	6,514	5,760	6,317	6,694	4,699	4,003	3,822	3,239	3,471
Cash & Equivalents	414	865	928	1,925	1,734	217	146	188	196	319
Note & Lease Receivable	2,558	2,228	1,970	1,778	1,531	1,828	1,608	1,548	1,472	1,275
Inventories, net	2,810	2,484	1,867	1,610	1,351	1,579	1,166	1,078	955	1,016
Prepaid Expenses	831	621	731	799	751	880	921	942	541	365
Current Deferred & Refundable Income Taxes	307	315	264	205	194	195	161	66	75	496
Plant, Property, & Equipment, net	3,294	2,859	2,446	2,252	2,084	2,079	1,782	1,697	1,630	1,490
Total Noncurrent Assets	29,182	25,762	24,264	23,661	21,999	23,787	15,216	13,523	13,227	13,172
Goodwill	17,089	14,387	12,920	11,988	9,951	10,176	7,911	6,998	6,678	6,473
Intangible Assets	6,684	6,003	5,902	6,121	5,917	7,886	6,372	5,837	5,883	6,194
Noncurrent Deferred & Refundable Income Taxes	3,655	3,841	3,942	4,142	4,210	4,196	87	-	-	-
Other Noncurrent Operating Assets	1,754	1,531	1,500	1,410	1,921	1,529	846	688	666	505
Total Liabilities & Shareholders' Equity	39,395	35,136	32,469	32,229	30,777	30,565	20,999	19,042	18,096	18,133
Total Liabilities	17,392	15,605	14,897	15,608	15,450	16,688	12,273	12,030	11,363	11,813
Total Current Liabilities	6,399	4,933	3,803	4,274	3,681	4,866	5,260	5,654	3,587	2,430
Short-Term Debt	1,778	531	20	261	13	1,416	2,253	1,801	64	3.00
Accounts Payable	960	942	862	794	513	542	349	530	447	209
Accrued Expenses	2,773	2,646	2,160	2,436	2,197	2,109	2,246	2,456	2,312	1,970
Other Current Liabilities	887	814	761	783	958	800	412	867	764	248
Total Noncurrent Liabilities	10,993	10,672	11,094	11,334	11,769	11,822	7,013	6,376	7,776	9,383
Long-Term Debt	8,968	8,571	8,915	8,804	9,130	8,592	4,803	3,815	5,420	5,674
Noncurrent Deferred & Payable Income Tax Liabilities	155	134	144	310	330	595	328	191	18	735
Other Noncurrent Operating Liabilities	1,870	1,967	2,035	2,220	2,309	2,635	1,882	2,370	2,338	2,974
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	22,003	19,530	17,573	16,622	15,326	13,877	8,726	7,012	6,733	6,320
Total Preferred & Common Equity	21,770	19,282	17,573	16,623	15,337	13,877	8,726	7,011	6,733	6,320
Preferred Stock	0.00	0.00	0.00	0.00	10	0.00	0.00	0.00	0.00	0.00
Total Common Equity	21,770	19,281	17,574	16,623	15,327	13,877	8,726	7,011	6,733	6,320
Common Stock	21,073	20,664	20,306	20,003	19,749	17,577	17,362	17,177	17,030	16,876
Retained Earnings	2,673	819	-750	-1,392	-2,378	-2,253	-6,953	-8,390	-8,581	-8,927
Treasury Stock	-2,251	-2,251	-2,251	-2,251	-2,251	-1,717	-1,717	-1,717	-1,717	-1,717
Accumulated Other Comprehensive Income / (Loss)	275	49	269	263	207	270	33	-59	1.00	88
Noncontrolling Interest	233	248	0.00	-	-	-	-	-	-	-

This table presents Boston Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	40,140	39,395	38,078	37,108	36,669	35,136	34,043	33,601	32,892	32,469	31,947
Total Current Assets	7,335	6,920	8,761	8,991	8,185	6,514	6,504	5,886	5,704	5,760	5,144
Cash & Equivalents	725	414	2,502	2,913	2,329	865	952	426	570	928	338
Note & Lease Receivable	2,693	2,558	2,501	2,400	2,304	2,228	2,101	2,134	2,076	1,970	1,871
Inventories, net	2,867	2,810	2,753	2,608	2,561	2,484	2,404	2,250	2,050	1,867	1,788
Prepaid Expenses	756	831	674	756	671	621	741	773	711	731	884
Current Deferred & Refundable Income Taxes	294	307	332	315	319	315	307	303	296	264	262
Plant, Property, & Equipment, net	3,389	3,294	3,072	2,951	2,897	2,859	2,635	2,534	2,478	2,446	2,273
Total Noncurrent Assets	29,416	29,182	26,245	25,166	25,588	25,762	24,902	25,182	24,711	24,264	24,530
Goodwill	17,340	17,089	15,033	14,397	14,361	14,387	13,608	13,659	13,269	12,920	12,852
Intangible Assets	6,566	6,684	5,754	5,417	5,839	6,003	5,849	6,063	6,060	5,902	6,058
Noncurrent Deferred & Refundable Income Taxes	3,676	3,655	3,816	3,801	3,792	3,841	3,840	3,865	3,900	3,942	4,018
Other Noncurrent Operating Assets	1,834	1,754	1,642	1,551	1,596	1,531	1,605	1,595	1,482	1,500	1,602
Total Liabilities & Shareholders' Equity	40,140	39,395	38,078	37,108	36,669	35,136	34,043	33,601	32,892	32,469	31,947
Total Liabilities	17,694	17,392	17,122	16,499	16,501	15,605	14,914	15,117	14,783	14,897	14,307
Total Current Liabilities	5,058	6,399	5,910	5,576	4,916	4,933	4,579	4,562	4,083	3,803	3,549
Short-Term Debt	777	1,778	1,652	1,580	1,085	531	513	559	510	20	20
Accounts Payable	1,004	960	907	906	921	942	929	899	868	862	803
Accrued Expenses	2,354	2,773	2,460	2,320	2,083	2,646	2,255	2,164	1,918	2,160	1,974
Other Current Liabilities	923	887	891	770	827	814	882	940	787	761	752
Total Noncurrent Liabilities	12,636	10,993	11,212	10,923	11,585	10,672	10,335	10,555	10,700	11,094	10,758
Long-Term Debt	10,532	8,968	9,233	8,991	9,534	8,571	8,386	8,494	8,495	8,915	8,564
Noncurrent Deferred & Payable Income Tax Liabilities	158	155	138	132	132	134	91	135	210	144	278
Other Noncurrent Operating Liabilities	1,946	1,870	1,841	1,800	1,919	1,967	1,858	1,926	1,995	2,035	1,916
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	22,446	22,003	20,956	20,609	20,168	19,530	19,129	18,485	18,109	17,573	17,640
Total Preferred & Common Equity	22,212	21,770	20,708	20,371	19,926	19,282	18,886	18,226	17,850	17,573	17,641
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	22,212	21,770	20,708	20,372	19,925	19,281	18,885	18,226	17,850	17,574	17,641
Common Stock	21,144	21,073	20,980	20,820	20,730	20,664	20,590	20,458	20,373	20,306	20,236
Retained Earnings	3,347	2,673	2,107	1,639	1,314	819	315	-189	-450	-750	-876
Treasury Stock	-2,251	-2,251	-2,251	-2,251	-2,251	-2,251	-2,251	-2,251	-2,251	-2,251	-2,251
Accumulated Other Comprehensive Income / (Loss)	-28	275	-128	164	132	49	231	208	178	269	532
Noncontrolling Interest	233	233	248	238	242	248	243	259	259	0.00	-

This table displays calculated financial ratios and metrics derived from Boston Scientific's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	17.61%	12.29%	6.68%	19.92%	-7.66%	9.28%	8.57%	7.89%	12.16%	1.31%
EBITDA Growth	13.64%	24.22%	9.24%	73.89%	-34.01%	-13.47%	27.15%	61.59%	184.05%	-0.45%
EBIT Growth	15.69%	39.66%	13.69%	402.48%	-75.69%	-30.20%	43.15%	183.17%	212.02%	-24.91%
NOPAT Growth	12.06%	86.28%	-12.95%	2,169.44%	-100.54%	486.83%	1,123.75%	-83.50%	542.36%	5.98%
Net Income Growth	15.95%	128.08%	-32.95%	1,369.51%	-101.74%	181.27%	1,506.73%	-70.03%	245.19%	-100.84%
EPS Growth	16.82%	137.78%	-34.78%	962.50%	-102.40%	179.83%	1,387.50%	-68.00%	238.89%	-100.00%
Operating Cash Flow Growth	37.24%	64.02%	-18.40%	24.01%	-17.86%	492.26%	-78.26%	20.64%	71.06%	-45.55%
Free Cash Flow Firm Growth	-703.36%	62.08%	19.09%	-149.81%	-14.70%	265.05%	-419.81%	-151.45%	130.27%	-842.56%
Invested Capital Growth	16.46%	8.55%	7.65%	9.99%	-8.72%	51.36%	25.69%	3.49%	2.94%	15.46%
Revenue Q/Q Growth	5.26%	3.51%	0.92%	3.65%	-1.94%	3.30%	1.57%	2.47%	2.61%	1.23%
EBITDA Q/Q Growth	5.32%	3.88%	9.41%	-7.02%	72.32%	10.41%	18.45%	27.13%	135.73%	475.21%
EBIT Q/Q Growth	4.50%	5.14%	18.72%	-12.15%	422.22%	-13.82%	4.79%	13.49%	3,253.85%	37.76%
NOPAT Q/Q Growth	3.23%	32.88%	-6.36%	18.33%	-200.00%	479.16%	137.12%	-87.68%	1,464.86%	48.45%
Net Income Q/Q Growth	3.30%	29.64%	6.89%	-9.87%	-102.21%	331.19%	149.40%	-87.66%	328.40%	39.65%
EPS Q/Q Growth	3.31%	30.49%	7.14%	-10.39%	-103.07%	332.47%	147.92%	-86.67%	316.67%	37.93%
Operating Cash Flow Q/Q Growth	17.00%	6.37%	27.49%	37.91%	-32.56%	57.87%	-68.21%	0.56%	27.65%	-2.81%
Free Cash Flow Firm Q/Q Growth	-994.32%	-236.90%	33.05%	-485.62%	179.94%	162.43%	-51.62%	-27.18%	74.86%	-10.39%
Invested Capital Q/Q Growth	10.21%	2.55%	-1.18%	0.69%	-5.58%	16.52%	6.03%	-4.75%	3.01%	-2.02%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	68.61%	69.49%	68.81%	68.78%	65.05%	70.98%	71.37%	71.34%	71.09%	70.94%
EBITDA Margin	23.43%	24.24%	21.91%	21.40%	14.76%	20.65%	26.08%	22.27%	14.87%	5.87%
Operating Margin	15.54%	16.45%	13.00%	10.09%	-0.81%	14.14%	15.33%	14.20%	5.33%	-3.78%
EBIT Margin	15.54%	15.80%	12.70%	11.92%	2.84%	10.81%	16.92%	12.83%	4.89%	-4.90%
Profit (Net Income) Margin	11.02%	11.18%	5.50%	8.76%	-0.83%	43.78%	17.01%	1.15%	4.14%	-3.20%
Tax Burden Percent	80.89%	80.20%	61.17%	96.75%	103.80%	684.13%	117.51%	11.15%	196.05%	36.77%
Interest Burden Percent	87.67%	88.22%	70.83%	75.94%	-28.01%	59.22%	85.56%	80.36%	43.17%	177.60%
Effective Tax Rate	19.11%	19.80%	38.83%	3.35%	0.00%	-584.13%	-17.51%	88.75%	-96.05%	0.00%
Return on Invested Capital (ROIC)	7.01%	7.05%	4.09%	5.11%	-0.25%	52.85%	12.61%	1.18%	7.40%	-1.82%
ROIC Less NNEP Spread (ROIC-NNEP)	4.21%	3.51%	-0.01%	3.35%	-0.57%	-15.24%	11.01%	0.42%	-2.55%	-2.73%
Return on Net Nonoperating Assets (RNNOA)	1.88%	1.54%	-0.01%	1.41%	-0.31%	-11.26%	8.63%	0.33%	-2.08%	-1.92%
Return on Equity (ROE)	8.89%	8.58%	4.08%	6.52%	-0.56%	41.59%	21.24%	1.51%	5.32%	-3.74%
Cash Return on Invested Capital (CROIC)	-8.20%	-1.15%	-3.28%	-4.41%	8.87%	11.98%	-10.16%	-2.24%	4.50%	-16.17%
Operating Return on Assets (OROA)	6.99%	6.66%	4.98%	4.50%	0.92%	4.50%	8.30%	6.25%	2.26%	-2.08%
Return on Assets (ROA)	4.95%	4.71%	2.16%	3.30%	-0.27%	18.23%	8.35%	0.56%	1.92%	-1.36%
Return on Common Equity (ROCE)	8.79%	8.52%	4.08%	6.52%	-0.56%	41.59%	21.23%	1.51%	5.32%	-3.74%
Return on Equity Simple (ROE_SIMPLE)	8.48%	8.26%	3.97%	6.26%	-0.53%	33.87%	19.15%	1.48%	5.15%	-3.78%
Net Operating Profit after Tax (NOPAT)	2,106	1,879	1,009	1,159	-56	10,385	1,770	145	876	-198
NOPAT Margin	12.57%	13.20%	7.95%	9.75%	-0.56%	96.74%	18.02%	1.60%	10.45%	-2.65%
Net Nonoperating Expense Percent (NNEP)	2.80%	3.54%	4.10%	1.76%	0.32%	68.09%	1.60%	0.76%	9.94%	0.91%
Return On Investment Capital (ROIC_SIMPLE)	6.43%	6.56%	3.81%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	31.39%	30.51%	31.19%	31.22%	34.95%	29.03%	28.64%	28.66%	28.91%	29.06%
SG&A Expenses to Revenue	35.73%	36.45%	35.64%	36.67%	38.20%	36.71%	36.33%	36.41%	36.95%	38.42%
R&D to Revenue	9.64%	9.93%	10.43%	10.13%	11.53%	10.94%	11.33%	11.02%	10.97%	11.72%
Operating Expenses to Revenue	53.07%	53.03%	55.82%	58.70%	65.85%	56.84%	56.03%	57.14%	65.76%	74.72%
Earnings before Interest and Taxes (EBIT)	2,603	2,250	1,611	1,417	282	1,160	1,662	1,161	410	-366
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3,923	3,452	2,779	2,544	1,463	2,217	2,562	2,015	1,247	439
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.05	4.39	3.77	3.64	3.36	4.54	5.60	4.86	4.37	3.92
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	7.86	5.95	5.23	5.09	5.19	5.87	4.98	3.76	3.51	3.32
Price to Earnings (P/E)	71.04	53.94	103.23	61.46	0.00	13.41	29.27	327.32	84.88	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.41%	1.85%	0.97%	1.63%	0.00%	7.46%	3.42%	0.31%	1.18%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.40	3.36	2.90	2.85	2.73	3.08	3.57	3.17	2.89	2.58
Enterprise Value to Revenue (EV/Rev)	8.49	6.54	5.86	5.69	5.94	6.78	5.68	4.36	4.14	4.03
Enterprise Value to EBITDA (EV/EBITDA)	36.25	26.99	26.73	26.60	40.26	32.85	21.79	19.59	27.86	68.71
Enterprise Value to EBIT (EV/EBIT)	54.63	41.41	46.11	47.76	208.85	62.78	33.58	34.00	84.73	0.00
Enterprise Value to NOPAT (EV/NOPAT)	67.54	49.58	73.63	58.40	0.00	7.01	31.54	272.93	39.64	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	41.40	37.23	48.68	36.19	39.06	39.66	180.04	27.68	29.39	43.65
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	29.33	30.93	0.00	0.00	65.14	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.49	0.47	0.51	0.55	0.60	0.72	0.81	0.80	0.81	0.90
Long-Term Debt to Equity	0.41	0.44	0.51	0.53	0.60	0.62	0.55	0.54	0.81	0.90
Financial Leverage	0.45	0.44	0.44	0.42	0.55	0.74	0.78	0.78	0.82	0.71
Leverage Ratio	1.79	1.82	1.89	1.97	2.10	2.28	2.54	2.70	2.78	2.75
Compound Leverage Factor	1.57	1.61	1.34	1.50	-0.59	1.35	2.18	2.17	1.20	4.89
Debt to Total Capital	32.81%	31.79%	33.71%	35.29%	37.37%	41.90%	44.71%	44.47%	44.89%	47.32%
Short-Term Debt to Total Capital	5.43%	1.85%	0.08%	1.02%	0.05%	5.93%	14.28%	14.26%	0.52%	0.03%
Long-Term Debt to Total Capital	27.38%	29.94%	33.63%	34.27%	37.31%	35.97%	30.43%	30.21%	44.36%	47.30%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.04%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.71%	0.87%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	66.48%	67.34%	66.30%	64.71%	62.64%	58.10%	55.29%	55.52%	55.11%	52.68%
Debt to EBITDA	2.74	2.64	3.22	3.56	6.25	4.51	2.75	2.79	4.40	12.93
Net Debt to EBITDA	2.63	2.39	2.88	2.81	5.06	4.42	2.70	2.69	4.24	12.21
Long-Term Debt to EBITDA	2.29	2.48	3.21	3.46	6.24	3.88	1.87	1.89	4.35	12.92
Debt to NOPAT	5.10	4.84	8.86	7.82	-163.27	0.96	3.99	38.83	6.26	-28.66
Net Debt to NOPAT	4.91	4.38	7.94	6.16	-132.30	0.94	3.90	37.53	6.03	-27.05
Long-Term Debt to NOPAT	4.26	4.56	8.84	7.60	-163.04	0.83	2.71	26.38	6.18	-28.64
Altman Z-Score	5.30	3.96	3.26	2.86	2.36	2.63	2.58	1.64	1.41	0.99
Noncontrolling Interest Sharing Ratio	1.16%	0.67%	-0.01%	-0.01%	0.00%	0.00%	0.01%	0.01%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.08	1.32	1.51	1.48	1.82	0.97	0.76	0.68	0.90	1.43
Quick Ratio	0.46	0.63	0.76	0.87	0.89	0.42	0.33	0.31	0.47	0.66
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2,465	-307	-809	-1,000	2,008	2,354	-1,426	-274	533	-1,762
Operating Cash Flow to CapEx	436.47%	354.03%	264.93%	346.30%	414.29%	404.41%	102.65%	447.02%	340.63%	279.76%
Free Cash Flow to Firm to Interest Expense	-8.08	-1.16	-1.72	-2.93	5.56	4.98	-5.92	-1.20	2.29	-6.20
Operating Cash Flow to Interest Expense	11.26	9.45	3.25	5.48	4.18	3.88	1.29	6.23	5.07	2.43
Operating Cash Flow Less CapEx to Interest Expense	8.68	6.78	2.02	3.90	3.17	2.92	0.03	4.83	3.58	1.56
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.42	0.39	0.38	0.32	0.42	0.49	0.49	0.46	0.43
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	1.99	2.00	2.28	2.51	2.37	2.27	2.51	2.55	2.46	2.22
Fixed Asset Turnover	5.44	5.37	5.40	5.48	4.76	5.56	5.65	5.44	5.38	4.99
Accounts Payable Turnover	5.53	4.82	4.78	5.68	6.57	6.99	6.40	5.31	7.39	9.23
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	183.78	182.75	160.40	145.62	154.32	160.77	145.58	143.09	148.39	164.78
Days Payable Outstanding (DPO)	66.03	75.77	76.40	64.28	55.57	52.18	57.03	68.76	49.39	39.56
Cash Conversion Cycle (CCC)	117.76	106.98	84.01	81.34	98.76	108.59	88.56	74.32	99.00	125.22
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	32,337	27,766	25,580	23,762	21,603	23,667	15,636	12,440	12,021	11,678
Invested Capital Turnover	0.56	0.53	0.51	0.52	0.44	0.55	0.70	0.74	0.71	0.69
Increase / (Decrease) in Invested Capital	4,571	2,186	1,818	2,159	-2,064	8,031	3,196	419	343	1,564
Enterprise Value (EV)	142,207	93,176	74,280	67,674	58,897	72,820	55,814	39,470	34,741	30,163
Market Capitalization	131,642	84,691	66,273	60,534	51,478	63,029	48,904	34,042	29,453	24,805
Book Value per Share	$14.77	$13.16	$12.27	$11.67	$10.70	$9.96	$6.31	$5.11	$4.94	$4.70
Tangible Book Value per Share	($1.36)	($0.76)	($0.87)	($1.04)	($0.38)	($3.00)	($4.02)	($4.24)	($4.28)	($4.72)
Total Capital	32,749	28,632	26,508	25,687	24,469	23,885	15,782	12,628	12,217	11,997
Total Debt	10,746	9,102	8,935	9,065	9,143	10,008	7,056	5,616	5,484	5,677
Total Long-Term Debt	8,968	8,571	8,915	8,804	9,130	8,592	4,803	3,815	5,420	5,674
Net Debt	10,332	8,237	8,007	7,140	7,409	9,791	6,910	5,428	5,288	5,358
Capital Expenditures (CapEx)	787	707	576	540	364	454	302	319	347	247
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,885	1,247	1,049	379	1,292	1,032	850	-219	-480	725
Debt-free Net Working Capital (DFNWC)	2,299	2,112	1,977	2,304	3,026	1,249	996	-31	-284	1,044
Net Working Capital (NWC)	521	1,581	1,957	2,043	3,013	-167	-1,257	-1,832	-348	1,041
Net Nonoperating Expense (NNE)	260	287	311	118	26	5,685	99	41	529	41
Net Nonoperating Obligations (NNO)	10,334	8,236	8,007	7,140	6,277	9,790	6,910	5,428	5,288	5,358
Total Depreciation and Amortization (D&A)	1,320	1,202	1,168	1,127	1,181	1,057	900	854	837	805
Debt-free, Cash-free Net Working Capital to Revenue	11.26%	8.76%	8.27%	3.19%	13.03%	9.61%	8.65%	-2.42%	-5.72%	9.70%
Debt-free Net Working Capital to Revenue	13.73%	14.83%	15.59%	19.38%	30.53%	11.63%	10.14%	-0.34%	-3.39%	13.96%
Net Working Capital to Revenue	3.11%	11.10%	15.43%	17.19%	30.39%	-1.56%	-12.80%	-20.25%	-4.15%	13.92%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.26	$1.08	$0.45	$0.69	($0.08)	$3.38	$1.21	$0.08	$0.26	($0.18)
Adjusted Weighted Average Basic Shares Outstanding	1.47B	1.45B	1.43B	1.42B	1.42B	1.39B	1.38B	1.37B	1.36B	1.34B
Adjusted Diluted Earnings per Share	$1.25	$1.07	$0.45	$0.69	($0.08)	$3.33	$1.19	$0.08	$0.25	($0.18)
Adjusted Weighted Average Diluted Shares Outstanding	1.49B	1.46B	1.44B	1.43B	1.42B	1.41B	1.40B	1.39B	1.38B	1.34B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$3.38	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.48B	1.47B	1.43B	1.43B	1.42B	1.40B	1.39B	1.37B	1.36B	1.35B
Normalized Net Operating Profit after Tax (NOPAT)	2,427	1,938	1,231	1,839	478	1,219	1,161	1,072	923	693
Normalized NOPAT Margin	14.49%	13.61%	9.71%	15.47%	4.82%	11.35%	11.82%	11.84%	11.01%	9.27%
Pre Tax Income Margin	13.63%	13.94%	9.00%	9.05%	-0.80%	6.40%	14.48%	10.31%	2.11%	-8.69%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	8.53	8.49	3.43	4.16	0.78	2.45	6.90	5.07	1.76	-1.29
NOPAT to Interest Expense	6.90	7.09	2.15	3.40	-0.16	21.96	7.34	0.63	3.76	-0.70
EBIT Less CapEx to Interest Expense	5.95	5.82	2.20	2.57	-0.23	1.49	5.64	3.68	0.27	-2.16
NOPAT Less CapEx to Interest Expense	4.32	4.42	0.92	1.81	-1.16	21.00	6.09	-0.76	2.27	-1.57
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	1.76%	7.88%	5.28%	-34.15%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	1.76%	7.88%	5.28%	-686.59%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Boston Scientific's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	20.93%	22.47%	19.34%	14.48%	13.78%	14.90%	11.26%	10.94%	12.00%	3.68%	8.12%
EBITDA Growth	31.80%	21.63%	7.67%	1.76%	23.55%	17.11%	63.55%	13.27%	9.37%	46.41%	-29.40%
EBIT Growth	31.02%	18.42%	10.67%	0.20%	33.01%	23.91%	119.87%	21.27%	17.01%	123.30%	-45.95%
NOPAT Growth	40.47%	11.26%	-10.43%	22.38%	40.65%	312.01%	108.84%	2.19%	17.36%	-0.51%	-18.17%
Net Income Growth	36.31%	11.71%	-7.14%	19.26%	57.01%	260.00%	168.09%	3.85%	185.45%	47.37%	-55.13%
EPS Growth	36.36%	11.76%	-5.88%	22.22%	57.14%	277.78%	183.33%	5.88%	200.00%	50.00%	-57.14%
Operating Cash Flow Growth	229.88%	52.14%	43.55%	23.56%	-13.68%	18.59%	48.51%	114.33%	427.59%	68.83%	1.08%
Free Cash Flow Firm Growth	-178.28%	-144.68%	-184.14%	9.76%	-210.70%	4.38%	69.36%	74.19%	82.99%	16.87%	-423.39%
Invested Capital Growth	16.07%	16.46%	8.37%	4.26%	7.21%	8.55%	4.60%	4.49%	3.22%	7.65%	9.69%
Revenue Q/Q Growth	2.21%	8.39%	2.16%	6.85%	3.52%	5.61%	-2.00%	6.20%	4.53%	2.27%	-2.28%
EBITDA Q/Q Growth	20.39%	1.99%	30.32%	-17.64%	11.10%	-9.71%	23.17%	0.00%	5.31%	26.09%	-14.69%
EBIT Q/Q Growth	31.41%	-9.64%	50.30%	-26.59%	18.77%	-15.56%	36.09%	-2.55%	10.65%	49.84%	-24.94%
NOPAT Q/Q Growth	18.56%	26.19%	28.90%	-27.16%	-6.09%	1.59%	76.11%	-16.28%	175.08%	-48.50%	-13.83%
Net Income Q/Q Growth	19.36%	20.30%	45.34%	-34.69%	-2.18%	0.00%	86.67%	-14.01%	124.29%	-25.53%	-27.69%
EPS Q/Q Growth	18.42%	18.75%	45.45%	-33.33%	-2.94%	0.00%	88.89%	-14.29%	133.33%	-25.00%	-29.41%
Operating Cash Flow Q/Q Growth	-62.84%	45.31%	23.25%	395.73%	-82.86%	37.11%	6.08%	246.32%	-76.46%	71.70%	53.09%
Free Cash Flow Firm Q/Q Growth	3.04%	-124.00%	-131.22%	44.59%	14.75%	-160.13%	26.56%	-90.79%	73.76%	16.64%	38.14%
Invested Capital Q/Q Growth	2.14%	10.21%	3.79%	-0.67%	2.49%	2.55%	-0.14%	2.14%	3.77%	-1.18%	-0.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	68.84%	67.84%	68.83%	69.17%	68.67%	69.23%	68.78%	70.63%	69.31%	68.85%	69.12%
EBITDA Margin	27.73%	23.54%	25.02%	19.61%	25.44%	23.70%	27.73%	22.06%	23.43%	23.26%	18.86%
Operating Margin	19.75%	14.80%	17.42%	12.62%	17.51%	15.68%	19.65%	14.28%	16.29%	12.40%	11.29%
EBIT Margin	19.02%	14.80%	17.75%	12.06%	17.56%	15.30%	19.14%	13.78%	15.02%	14.19%	9.68%
Profit (Net Income) Margin	14.41%	12.34%	11.12%	7.82%	12.79%	13.53%	14.29%	7.50%	9.27%	4.32%	5.93%
Tax Burden Percent	83.48%	96.24%	69.96%	76.67%	81.09%	99.80%	82.62%	63.38%	70.72%	35.44%	76.73%
Interest Burden Percent	90.76%	86.67%	89.56%	84.51%	89.81%	88.60%	90.37%	85.89%	87.23%	85.87%	79.80%
Effective Tax Rate	16.52%	3.93%	29.90%	23.33%	18.91%	0.20%	17.21%	36.62%	29.50%	64.81%	23.27%
Return on Invested Capital (ROIC)	9.41%	7.92%	6.89%	5.32%	7.59%	8.35%	8.45%	4.57%	5.73%	2.24%	4.40%
ROIC Less NNEP Spread (ROIC-NNEP)	8.39%	7.00%	6.32%	4.38%	6.94%	7.38%	7.59%	3.93%	4.87%	2.22%	3.27%
Return on Net Nonoperating Assets (RNNOA)	3.72%	3.13%	2.58%	1.82%	3.03%	3.23%	3.34%	1.90%	2.43%	0.99%	1.48%
Return on Equity (ROE)	13.13%	11.05%	9.46%	7.15%	10.62%	11.59%	11.79%	6.48%	8.17%	3.23%	5.88%
Cash Return on Invested Capital (CROIC)	-7.30%	-8.20%	-0.80%	3.42%	0.43%	-1.15%	0.85%	-0.24%	1.01%	-3.28%	-4.89%
Operating Return on Assets (OROA)	8.69%	6.65%	7.83%	5.20%	7.42%	6.45%	7.98%	5.61%	6.01%	5.56%	3.81%
Return on Assets (ROA)	6.59%	5.55%	4.91%	3.37%	5.41%	5.70%	5.96%	3.06%	3.71%	1.69%	2.34%
Return on Common Equity (ROCE)	12.98%	10.92%	9.35%	7.06%	10.48%	11.51%	11.71%	6.43%	8.11%	3.23%	5.88%
Return on Equity Simple (ROE_SIMPLE)	9.12%	0.00%	8.63%	8.95%	8.89%	0.00%	6.50%	5.00%	5.05%	0.00%	3.70%
Net Operating Profit after Tax (NOPAT)	769	648	514	399	547	583	574	326	389	141	275
NOPAT Margin	16.49%	14.21%	12.21%	9.68%	14.19%	15.65%	16.27%	9.05%	11.48%	4.36%	8.67%
Net Nonoperating Expense Percent (NNEP)	1.03%	0.92%	0.56%	0.94%	0.65%	0.97%	0.86%	0.64%	0.86%	0.02%	1.13%
Return On Investment Capital (ROIC_SIMPLE)	2.28%	1.98%	-	-	-	2.04%	-	-	-	0.53%	-
Cost of Revenue to Revenue	31.16%	32.14%	31.17%	30.83%	31.35%	30.77%	31.22%	29.40%	30.69%	31.18%	30.88%
SG&A Expenses to Revenue	34.25%	35.34%	37.11%	35.10%	35.37%	37.02%	35.21%	37.62%	35.85%	35.87%	35.71%
R&D to Revenue	9.50%	10.06%	9.67%	9.30%	9.49%	9.72%	10.09%	9.98%	9.94%	10.18%	10.69%
Operating Expenses to Revenue	49.07%	53.05%	51.41%	56.55%	51.17%	53.53%	49.14%	56.35%	53.02%	56.48%	57.82%
Earnings before Interest and Taxes (EBIT)	887	675	747	497	677	570	675	496	509	460	307
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,293	1,074	1,053	808	981	883	978	794	794	754	598
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.70	6.05	5.96	5.56	0.00	4.39	4.09	4.27	4.02	3.77	3.14
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	202.90	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	8.48	7.86	7.76	7.43	0.00	5.95	5.62	5.80	5.50	5.23	4.41
Price to Earnings (P/E)	73.27	71.04	68.87	61.94	0.00	53.94	64.86	90.32	84.85	103.23	92.88
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.36%	1.41%	1.45%	1.61%	0.00%	1.85%	1.54%	1.11%	1.18%	0.97%	1.08%
Enterprise Value to Invested Capital (EV/IC)	4.83	4.40	4.50	4.28	0.00	3.36	3.16	3.20	3.03	2.90	2.46
Enterprise Value to Revenue (EV/Rev)	9.10	8.49	8.30	7.95	0.00	6.54	6.22	6.47	6.17	5.86	5.07
Enterprise Value to EBITDA (EV/EBITDA)	37.39	36.25	35.45	33.18	0.00	26.99	25.73	29.44	28.42	26.73	25.08
Enterprise Value to EBIT (EV/EBIT)	56.05	54.63	53.01	50.07	0.00	41.41	39.95	48.90	47.76	46.11	46.94
Enterprise Value to NOPAT (EV/NOPAT)	68.62	67.54	64.73	57.56	0.00	49.58	60.46	78.74	73.65	73.63	59.12
Enterprise Value to Operating Cash Flow (EV/OCF)	41.89	41.40	44.97	46.02	0.00	37.23	36.34	40.78	45.36	48.68	53.21
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	127.75	0.00	0.00	381.43	0.00	305.15	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.50	0.49	0.52	0.51	0.53	0.47	0.47	0.49	0.50	0.51	0.49
Long-Term Debt to Equity	0.47	0.41	0.44	0.44	0.47	0.44	0.44	0.46	0.47	0.51	0.49
Financial Leverage	0.44	0.45	0.41	0.42	0.44	0.44	0.44	0.48	0.50	0.44	0.45
Leverage Ratio	1.80	1.79	1.80	1.81	1.82	1.82	1.79	1.84	1.87	1.89	1.87
Compound Leverage Factor	1.64	1.56	1.61	1.53	1.63	1.61	1.62	1.58	1.63	1.62	1.49
Debt to Total Capital	33.50%	32.81%	34.19%	33.90%	34.49%	31.79%	31.75%	32.87%	33.21%	33.71%	32.73%
Short-Term Debt to Total Capital	2.30%	5.43%	5.19%	5.07%	3.52%	1.85%	1.83%	2.03%	1.88%	0.08%	0.08%
Long-Term Debt to Total Capital	31.20%	27.38%	29.00%	28.84%	30.97%	29.94%	29.92%	30.84%	31.33%	33.63%	32.66%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.69%	0.71%	0.78%	0.76%	0.79%	0.87%	0.87%	0.94%	0.96%	0.00%	0.00%
Common Equity to Total Capital	65.80%	66.48%	65.04%	65.34%	64.72%	67.34%	67.38%	66.18%	65.83%	66.30%	67.27%
Debt to EBITDA	2.65	2.74	2.92	2.90	2.92	2.64	2.68	3.08	3.18	3.22	3.38
Net Debt to EBITDA	2.48	2.63	2.25	2.10	2.28	2.39	2.39	2.93	2.98	2.88	3.25
Long-Term Debt to EBITDA	2.47	2.29	2.48	2.46	2.62	2.48	2.52	2.89	3.00	3.21	3.37
Debt to NOPAT	4.86	5.10	5.34	5.02	5.22	4.84	6.29	8.23	8.24	8.86	7.97
Net Debt to NOPAT	4.55	4.91	4.11	3.64	4.08	4.38	5.62	7.84	7.72	7.94	7.65
Long-Term Debt to NOPAT	4.53	4.26	4.53	4.27	4.69	4.56	5.93	7.72	7.77	8.84	7.95
Altman Z-Score	5.74	5.13	4.97	4.74	0.00	3.80	3.66	3.57	3.40	3.15	2.77
Noncontrolling Interest Sharing Ratio	1.12%	1.16%	1.23%	1.27%	1.31%	0.67%	0.66%	0.72%	0.74%	-0.01%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.45	1.08	1.48	1.61	1.67	1.32	1.42	1.29	1.40	1.51	1.45
Quick Ratio	0.68	0.46	0.85	0.95	0.94	0.63	0.67	0.56	0.65	0.76	0.62
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-3,803	-3,923	-1,751	-757	-1,367	-1,603	-616	-839	-440	-1,677	-2,011
Operating Cash Flow to CapEx	289.30%	529.45%	559.78%	524.52%	92.13%	358.43%	369.31%	460.14%	175.93%	384.29%	315.44%
Free Cash Flow to Firm to Interest Expense	-46.38	-49.03	-22.17	-9.84	-19.81	-25.05	-9.34	-11.99	-6.77	-26.20	-31.93
Operating Cash Flow to Interest Expense	6.60	18.20	12.68	10.56	2.38	14.95	10.58	9.40	2.92	12.61	7.46
Operating Cash Flow Less CapEx to Interest Expense	4.32	14.76	10.42	8.55	-0.20	10.78	7.71	7.36	1.26	9.33	5.10
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.46	0.45	0.44	0.43	0.42	0.42	0.42	0.41	0.40	0.39	0.39
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	2.03	1.99	1.91	1.95	1.96	2.00	2.01	2.04	2.13	2.28	2.31
Fixed Asset Turnover	5.59	5.44	5.58	5.55	5.47	5.37	5.61	5.61	5.50	5.40	5.74
Accounts Payable Turnover	5.72	5.53	5.38	5.24	5.05	4.82	4.86	5.01	5.17	4.78	5.30
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	180.08	183.78	190.63	187.60	186.42	182.75	181.72	178.66	170.98	160.40	157.99
Days Payable Outstanding (DPO)	63.86	66.03	67.87	69.70	72.33	75.77	75.08	72.81	70.63	76.40	68.82
Cash Conversion Cycle (CCC)	116.21	117.76	122.76	117.90	114.09	106.98	106.64	105.85	100.35	84.01	89.18
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	33,030	32,337	29,340	28,268	28,458	27,766	27,075	27,112	26,544	25,580	25,885
Invested Capital Turnover	0.57	0.56	0.56	0.55	0.53	0.53	0.52	0.51	0.50	0.51	0.51
Increase / (Decrease) in Invested Capital	4,572	4,571	2,265	1,156	1,914	2,186	1,190	1,165	829	1,818	2,286
Enterprise Value (EV)	159,693	142,207	132,037	121,115	0.00	93,176	85,501	86,651	80,476	74,280	63,692
Market Capitalization	148,876	131,642	123,406	113,219	0.00	84,691	77,311	77,765	71,782	66,273	55,446
Book Value per Share	$15.05	$14.77	$14.06	$13.86	$13.57	$13.16	$12.90	$12.68	$12.44	$12.27	$12.32
Tangible Book Value per Share	($1.15)	($1.36)	($0.05)	$0.38	($0.19)	($0.76)	($0.39)	($1.04)	($1.03)	($0.87)	($0.89)
Total Capital	33,755	32,749	31,841	31,180	30,787	28,632	28,028	27,538	27,114	26,508	26,224
Total Debt	11,309	10,746	10,885	10,571	10,619	9,102	8,899	9,053	9,005	8,935	8,584
Total Long-Term Debt	10,532	8,968	9,233	8,991	9,534	8,571	8,386	8,494	8,495	8,915	8,564
Net Debt	10,584	10,332	8,383	7,658	8,290	8,237	7,947	8,627	8,435	8,007	8,246
Capital Expenditures (CapEx)	187	275	179	155	178	267	189	143	108	210	149
Debt-free, Cash-free Net Working Capital (DFCFNWC)	2,329	1,885	2,001	2,082	2,025	1,247	1,486	1,457	1,561	1,049	1,277
Debt-free Net Working Capital (DFNWC)	3,054	2,299	4,503	4,995	4,354	2,112	2,438	1,883	2,131	1,977	1,615
Net Working Capital (NWC)	2,277	521	2,851	3,415	3,269	1,581	1,925	1,324	1,621	1,957	1,595
Net Nonoperating Expense (NNE)	97	85	46	77	54	79	70	56	75	1.46	87
Net Nonoperating Obligations (NNO)	10,584	10,334	8,384	7,659	8,290	8,236	7,946	8,627	8,435	8,007	8,245
Total Depreciation and Amortization (D&A)	406	399	306	311	304	313	303	298	285	294	291
Debt-free, Cash-free Net Working Capital to Revenue	13.27%	11.26%	12.58%	13.67%	13.77%	8.76%	10.80%	10.87%	11.97%	8.27%	10.16%
Debt-free Net Working Capital to Revenue	17.40%	13.73%	28.30%	32.80%	29.61%	14.83%	17.72%	14.05%	16.34%	15.59%	12.85%
Net Working Capital to Revenue	12.97%	3.11%	17.92%	22.43%	22.23%	11.10%	13.99%	9.88%	12.43%	15.43%	12.69%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.46	$0.38	$0.32	$0.22	$0.34	$0.35	$0.34	$0.18	$0.21	$0.09	$0.12
Adjusted Weighted Average Basic Shares Outstanding	1.48B	1.47B	1.47B	1.47B	1.47B	1.45B	1.46B	1.45B	1.44B	1.43B	1.43B
Adjusted Diluted Earnings per Share	$0.45	$0.38	$0.32	$0.22	$0.33	$0.34	$0.34	$0.18	$0.21	$0.09	$0.12
Adjusted Weighted Average Diluted Shares Outstanding	1.49B	1.49B	1.49B	1.48B	1.48B	1.46B	1.48B	1.46B	1.45B	1.44B	1.44B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.48B	1.48B	1.47B	1.47B	1.47B	1.47B	1.46B	1.46B	1.44B	1.43B	1.43B
Normalized Net Operating Profit after Tax (NOPAT)	781	651	503	613	564	616	505	384	412	354	389
Normalized NOPAT Margin	16.76%	14.28%	11.96%	14.87%	14.61%	16.53%	14.32%	10.67%	12.15%	10.90%	12.27%
Pre Tax Income Margin	17.26%	12.82%	15.89%	10.19%	15.77%	13.56%	17.30%	11.84%	13.10%	12.18%	7.73%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	10.82	8.44	9.46	6.45	9.81	8.91	10.23	7.09	7.83	7.19	4.87
NOPAT to Interest Expense	9.38	8.11	6.50	5.18	7.93	9.11	8.69	4.65	5.99	2.21	4.36
EBIT Less CapEx to Interest Expense	8.54	5.00	7.19	4.44	7.23	4.73	7.36	5.04	6.17	3.91	2.51
NOPAT Less CapEx to Interest Expense	7.10	4.67	4.24	3.16	5.35	4.94	5.83	2.61	4.33	-1.07	2.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.79%	1.76%	3.34%	6.03%	6.10%	7.88%	8.42%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.79%	1.76%	3.34%	6.03%	6.10%	7.88%	8.42%

Frequently Asked Questions About Boston Scientific's Financials

When does Boston Scientific's financial year end?

According to the most recent income statement we have on file, Boston Scientific's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Boston Scientific's net income changed over the last 9 years?

Boston Scientific's net income appears to be on an upward trend, with a most recent value of $1.85 billion in 2024, falling from -$239 million in 2015. The previous period was $1.59 billion in 2023. See where experts think Boston Scientific is headed by visiting Boston Scientific's forecast page.

What is Boston Scientific's operating income?

Boston Scientific's total operating income in 2024 was $2.60 billion, based on the following breakdown:

Total Gross Profit: $11.49 billion
Total Operating Expenses: $8.89 billion

How has Boston Scientific revenue changed over the last 9 years?

Over the last 9 years, Boston Scientific's total revenue changed from $7.48 billion in 2015 to $16.75 billion in 2024, a change of 124.0%.

How much debt does Boston Scientific have?

Boston Scientific's total liabilities were at $17.39 billion at the end of 2024, a 11.5% increase from 2023, and a 47.2% increase since 2015.

How much cash does Boston Scientific have?

In the past 9 years, Boston Scientific's cash and equivalents has ranged from $146 million in 2018 to $1.93 billion in 2021, and is currently $414 million as of their latest financial filing in 2024.

How has Boston Scientific's book value per share changed over the last 9 years?

Over the last 9 years, Boston Scientific's book value per share changed from 4.70 in 2015 to 14.77 in 2024, a change of 214.4%.

Related Companies

This page (NYSE:BSX) was last updated on 5/27/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boston Scientific (BSX) Financials

Frequently Asked Questions About Boston Scientific's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Boston Scientific (BSX) Financials

Annual Income Statements for Boston Scientific

Quarterly Income Statements for Boston Scientific

Annual Cash Flow Statements for Boston Scientific

Quarterly Cash Flow Statements for Boston Scientific

Annual Balance Sheets for Boston Scientific

Quarterly Balance Sheets for Boston Scientific

Annual Metrics And Ratios for Boston Scientific

Quarterly Metrics And Ratios for Boston Scientific

Frequently Asked Questions About Boston Scientific's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools